- Home
- CHCT vs CELC Comparison
CHCT vs CELC Comparison
Compare CHCT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- CELC
- Stock Information
- Founded
- CHCT 2014
- CELC 2011
- Country
- CHCT United States
- CELC United States
- Employees
- CHCT N/A
- CELC N/A
- Industry
- CHCT Real Estate Investment Trusts
- CELC Medical Specialities
- Sector
- CHCT Real Estate
- CELC Health Care
- Exchange
- CHCT Nasdaq
- CELC Nasdaq
- Market Cap
- CHCT 491.1M
- CELC 440.0M
- IPO Year
- CHCT 2015
- CELC 2017
- Fundamental
- Price
- CHCT $16.40
- CELC $14.05
- Analyst Decision
- CHCT Buy
- CELC Strong Buy
- Analyst Count
- CHCT 4
- CELC 6
- Target Price
- CHCT $21.00
- CELC $30.67
- AVG Volume (30 Days)
- CHCT 245.7K
- CELC 242.6K
- Earning Date
- CHCT 07-29-2025
- CELC 08-13-2025
- Dividend Yield
- CHCT 11.46%
- CELC N/A
- EPS Growth
- CHCT N/A
- CELC N/A
- EPS
- CHCT N/A
- CELC N/A
- Revenue
- CHCT $116,531,000.00
- CELC N/A
- Revenue This Year
- CHCT $7.71
- CELC N/A
- Revenue Next Year
- CHCT $7.53
- CELC N/A
- P/E Ratio
- CHCT N/A
- CELC N/A
- Revenue Growth
- CHCT 1.33
- CELC N/A
- 52 Week Low
- CHCT $14.76
- CELC $7.58
- 52 Week High
- CHCT $27.62
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- CHCT 45.91
- CELC 64.62
- Support Level
- CHCT $15.92
- CELC $13.47
- Resistance Level
- CHCT $16.57
- CELC $14.57
- Average True Range (ATR)
- CHCT 0.46
- CELC 0.63
- MACD
- CHCT -0.07
- CELC -0.01
- Stochastic Oscillator
- CHCT 28.24
- CELC 63.83
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.